Graves’ ophthalmopathy after total thyroidectomy for papillary carcinoma

Giovansili, Lama; Cayrolle, G.; Belangé, G; Clavel, Gaëlle; Herdan, M L

doi:10.1016/j.ando.2010.11.001

Cited by 8 publications

(8 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In one patient after treatment we observed an increase of TRAb, while a reduction of these antibodies in 6 other patients was noticed. Despite the described TRAb increase following radioiodine therapy for Graves disease [31,32] and in thyroid cancers [33,34], autonomous thyroid disease [35], as well as nontoxic goitre [36], we did not obtain such results. Long observation time, assessment at only two time points, or advanced patient's age may be of importance for these results.…”

Section: Discussioncontrasting

confidence: 46%

Wole guzowate olbrzymie — ambulatoryjne leczenie radiojodem

Kaniuka-Jakubowska

Lewczuk

Mizan-Gross

et al. 2015

Endokrynologia Polska

View full text Add to dashboard Cite

Introduction: 131-I treatment of nodular, especially nontoxic, goitre is still reserved mainly for elderly patients, whose numerous concomitant diseases disqualify them from surgery. Therapy often involves isolation and is available only in selected centres, which may be located far from some patients' places of residence, which is inconvenient for elderly people. The aim of the study was to assess the effectiveness of outpatient fractionated 131-I treatment of patients with large nodular goitres, as well as to evaluate complications and the factors affecting treatment results. Material and methods:The study included 35 patients with a large nodular goitre. Thyroid volume and treatment results were evaluated using US and CT neck examination.

show abstract

Section: Discussioncontrasting

confidence: 46%

Wole guzowate olbrzymie — ambulatoryjne leczenie radiojodem

Kaniuka-Jakubowska

Lewczuk

Mizan-Gross

et al. 2015

Endokrynologia Polska

View full text Add to dashboard Cite

show abstract

“…However, Bartalena and Tanda [12] reported that TAO may occur in patients with no thyroid dysfunction. Only three case reports of TAO after RAI for thyroid carcinoma have been reported [5][6][7], and all were treated with an ablative dose (2.2 to 3.7 GBq). Despite the absence of thyroid tissue after total thyroidectomy for nonmetastatic thyroid carcinoma, TAO occurred after RAI [6,7].…”

Section: Discussionmentioning

confidence: 99%

“…Lenvatinib is also an orally administered inhibitor of VEGFR-1, -2, and -3, fibroblast growth factor receptor-1 to -4, PDGFR-α, RET, and KIT [4]. TAO after RAI for thyroid carcinoma after total thyroidectomy has been reported in a few studies [5][6][7]; however, the improvement in TAO during the course of sorafenib and lenvatinib treatment for metastases of RAI-refractory differentiated thyroid carcinoma after total thyroidectomy has not been reported.…”

Section: Introductionmentioning

confidence: 99%

Thyroid-Associated Ophthalmopathy after Radioactive Iodine Therapy for Metastatic Follicular Thyroid Carcinoma

Murayama

Toda

Okubo

et al. 2021

Case Reports in Endocrinology

View full text Add to dashboard Cite

Thyroid-associated ophthalmopathy (TAO) is an inflammation of the extraocular muscles and periorbital connective tissue caused by autoantibodies against common antigens to both the thyroid and orbit. The release of antigens and induction of hypothyroidism caused by radioactive iodine (RAI) therapy may exacerbate TAO. Here, we present the case of a 67-year-old-woman treated with RAI therapy for metastatic follicular thyroid carcinoma who presented with TAO during the course of sorafenib administration. Tg and TgAb levels were gradually decreased with sorafenib and lenvatinib treatment, and TAO was improved without any ophthalmologic treatment.

show abstract

“…Coexistence of GD with GO and thyroid cancer is rare [1,13,14]. In 1 of the 3 previously reported cases, GO evolved under levothyroxine suppression, but improved with intravenous glucocorticoid pulse therapy [13].…”

Section: Discussionmentioning

confidence: 99%

“…The coexistence of GD with GO and thyroid cancer seems rare, with only 3 reported cases [1,13,14]. rhTSH is used routinely for radioiodine ablation in patients with thyroid cancer, obviating the need for hormone withdrawal and a period of hypothyroidism.…”

Section: Introductionmentioning

confidence: 99%

Is Recombinant Human TSH a Trigger for Graves Orbitopathy?

2012

View full text Add to dashboard Cite

The pathogenesis of Graves’ orbitopathy (GO) remains unknown. The hypothesis of a causal relationship between autoimmunity against the TSH receptor (TSHR) and GO is supported by clinical studies. Radioiodine treatment is associated with worsening or new onset of GO, possibly via antigen shedding or by inducing hypothyroidism. The coexistence of thyroid cancer with Graves’ disease (GD) and GO is rare. Here we report 3 cases of reactivation of GO in patients who underwent treatment with recombinant human TSH (rhTSH) and radioiodine ablation. In each case, a thyroidectomy was performed to treat the GD, and an incidental thyroid cancer was discovered. In all 3 cases, reactivation of GO was observed 3–6 weeks after administration of rhTSH, despite maintaining euthyroidism, which was unaccompanied by a rise in serum TSHR antibodies after radioiodine and despite steroids in 1 of the 3 patients. These observations suggest that binding of either TSH or TSHR antibodies to the TSHR, independently of thyroid status, may be causally related to deterioration of GO. Clinicians should be aware of a possible association between rhTSH administration and reactivation of GO, which should be taken into account before prescribing rhTSH in patients with GO. Prophylactic steroids may need to be considered for patients at high risk of exacerbation of GO.

show abstract

Graves’ ophthalmopathy after total thyroidectomy for papillary carcinoma

Cited by 8 publications

References 14 publications

Wole guzowate olbrzymie — ambulatoryjne leczenie radiojodem

Wole guzowate olbrzymie — ambulatoryjne leczenie radiojodem

Thyroid-Associated Ophthalmopathy after Radioactive Iodine Therapy for Metastatic Follicular Thyroid Carcinoma

Is Recombinant Human TSH a Trigger for Graves Orbitopathy?

Contact Info

Product

Resources

About

Graves’ ophthalmopathy after total thyroidectomy for papillary carcinoma

Cited by 8 publications

References 14 publications

Wole guzowate olbrzymie — ambulatoryjne leczenie radiojodem

Wole guzowate olbrzymie — ambulatoryjne leczenie radiojodem

Thyroid-Associated Ophthalmopathy after Radioactive Iodine Therapy for Metastatic Follicular Thyroid Carcinoma

Is Recombinant Human TSH a Trigger for Graves Orbitopathy?

Contact Info

Product

Resources

About

Is Recombinant Human TSH a Trigger for Graves Orbitopathy?